Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS ...

WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global ...

Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking ...

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...

Gilead has won FDA approval for an HIV prevention shot that is administered only once every six months. When will low-income ...

Gilead is now waiting for regulatory decisions on the twice-yearly PrEP in Europe and other markets, including South Africa ...

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.

Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") ...